About Us

About Bio-ReCell

Bio-ReCell is at the cutting edge of biotechnology, leading the advancement towards improved isolation of specific cell types from complex mixtures. Our team comprises experts who are pioneers in their field. United by our shared passion for Cell Biology, we are dedicated to bringing the benefits of our technological innovations to the world.

OUR HISTORY

FOUNDING
Our journey began in the bustling heart of Ljubljana in late 2018, where we undertook ambitious projects continuously demonstrating our commitment to innovation. Despite challenges, we grew stronger and more resilient, continually pushing the limits and working on groundbreaking technologies.

NEW HORIZONS
In 2023, we reached a pivotal moment and chose to relocate our operations. This significant move symbolized our growth and marked a new chapter in our journey. The grand opening at the new site was graced by Slovenian President Nataša Pirc Musar, underscoring national recognition and support for our work.

ATRACT PRODUCT LAUNCH
Through hard work and determination, we successfully launched our first product, the T-cell activation kit named Atract. This launch is a significant achievement, representing our progress and paving the way for future releases.

WHAT WE DO

SVF Development
This department studies the Stromal Vascular Fraction (SVF) from body fat, which contains a diverse mix of cells like stem cells and immune cells. Their focus is on the therapeutic potential of SVF, especially in regenerating various cell types and improving quality of life through treatments like knee osteoarthritis relief.

T-cell Activation
This team is dedicated to enhancing the immune system's effectiveness against infections and cancer by activating T-cells. Given the immune system's role in fighting diseases, this process is crucial for health and well-being.

Cell separation
The third department specializes in isolating specific cell populations from mixed cell groups. This process is vital in cell biology research, diagnostics, and therapeutic applications.

OUR TECHNOLOGY

At Bio-ReCell, we revolutionized cell separation with our unique biocomposite material, covalently bonded with specific antibodies for precise cell targeting. A crowning achievement at Bio-ReCell is our innovative, magnet-free cell separation device that achieves over 90% purity in under 30 minutes and features a user-friendly touchscreen interface. This magnet-free system is ideal for research and preclinical work and is customizable for large-scale applications, setting a new standard in cell isolation technology.

THE FUTURE

We embrace the future with optimism and pride and are eager to reach more remarkable milestones on our journey. We are particularly thrilled about bringing our products into clinical settings to benefit patients with diseases like cancer and osteoporosis.

MORE ABOUT OUR PRODUCTS

To discover more about Bio-ReCell, visit our product page or contact us at support@bio-recell.com.

EXECUTIVE TEAM

Dr. Luka Fajs

Chief Executive Officer & Head of Reaserch

Luka is an award-winning serial entrepreneur, inventor and medical device CEO. Luka Fajs holds a Ph.D. in microbiology and has extensive experience in point-of-care technologies in diagnostics and cell therapy. His primary responsibilities are leading medical device R&D, fundraising and business development. Luka joined Bio-ReCell in 2020 from Eclipse Diagnostics, which he co-founded. Luka is also a qualified BSL 3 and 4 agent specialist.

Prof. Dr. Stephen Minger, PhD

Cofounder & Chief Scientific Officer

Dr. Stephen Minger is a pioneering researcher in human stem cell biology, renowned for his work in cell and gene therapy, human embryonic stem biology and regenerative medicine. He holds a PhD in Pathology (Neurosciences) from Albert Einstein College of Medicine, followed by post-doctoral research at UCSD, specializing in central nervous system gene therapy and neural stem cell biology. Transitioning to King’s College London, he ascended to Senior Lecturer in Stem Cell Biology and directed the Stem Cell Biology Laboratory. Beyond academia, Stephen was the Global Director for R&D for Cell Technologies at GE Healthcare and later held the position of Chief Scientist at GE Healthcare Life Sciences. Currently, he is the Founder and Director of SLM Blue Skies Innovations Ltd, providing expert analysis in emerging healthcare technologies, including gene and cell-based therapies, machine-brain interfaces, AI, and pluripotent stem cell technologies.

Barbara Vtič

Chief Financial Officer

Barbara is a seasoned leader with a master's degree in Economics and a proven track record of over 17 years in executive positions. Her expertise is primarily in finance, but also legal affairs, human resources, and strategic management.Throughout her career, Barbara has undertaken pivotal roles such as financial manager, financial consultant, chief restructuring manager, and director in several SME's and med-tech startups. Demonstrating proficiency in financial and strategic planning, she currently oversees financial operations, investor relations, and collaborative initiatives with key stakeholders of the Bio-ReCell company.Barbara's commitment to innovation is evident in her strategic direction for Bio-ReCell. Leveraging her comprehensive knowledge of financial management, Barbara plays a vital role in steering the company toward continued success.

ADVISORY BOARD

Prof. Dr. Stephen Minger, PhD

Cofounder & Chief Scientific Officer

Prof. Dr. Frank Barry

Professor of Cellular Therapy

Prof. Dr. Frank Barry is a pioneering figure in regenerative medicine. His innovative cellular therapies for tissue repair, joint injury, and arthritis have made a significant impact. As a board member and advisor, he influences research and development in Europe and North America. He is known for his research on mesenchymal stromal cells, cell expansion methods, and clinical protocols. His work in cell technology and arthritic disease therapeutics is widely recognized and highly cited, earning him the prestigious Marshall Urist Award for tissue regeneration excellence from the Orthopaedic Research Society.

Dr. Shannon Eaker

Ph.D. in Biochemistry, Cellular and Molecular Biology

Dr. Shannon Eaker is a seasoned expert in the domains of T-cell, HSC (Hematopoietic Stem Cell), and ES/iPSC (Embryonic Stem/Induced Pluripotent Stem Cell) biology. With over 11 years of experience at Cytiva Cell and Gene Therapy, he has emerged as a distinguished leader in the field. As a member of ISCT’s Process and Product Development committee, Shannon actively contributes to advancing the industry. He combines academic rigor with industry leadership and has authored numerous impactful papers in cell biology and manufacturing.

Dr. Paul Kemp

Director & CEO at HairClone

Paul Kemp is a distinguished figure in the field of Regenerative Medicine with over 25 years of extensive commercialization experience in both the US and UK markets. He is globally recognized as a pioneer in the field and has made significant contributions to cellular therapies. Paul is notably the lead inventor of the first multi-cell therapy, marking a groundbreaking achievement in the industry.

Prof. Dr. Majlinda Lako

Professor of Stem Cell Sciences at Newcastle University

Prof. Majlinda Lako is a renowned stem cell researcher whose work encompasses critical areas in stem cell biology and regenerative medicine. Her expertise includes self-renewal in pluripotent stem cells, hematopoietic differentiation and clinical applications for corneal and retinal blindness. She boasts an extensive publication record and has established multiple iPSC lines, used worldwide for various applications. Majlinda has made substantial strides in corneal stem cell therapy, successfully treating patients, and actively contributes to mentoring, lecturing, and shaping stem cell infrastructure and governmental policies.

Prof. Dr. Mark Lowdell

Professor of Cell & Tissue Therapy at University College London

Prof. Dr. Mark Lowdell is a distinguished figure with a rich academic background. His expertise encompasses cutting-edge research and development in cell and tissue therapies. With over 35 years of experience, he has made significant contributions to adoptive immunotherapy, GMP facility establishment and advisory roles for key ATMP (Advanced Therapy Medicinal Product) development companies as CSO (Chief Scientific Officer) or member of the SAB or MAB. Mark continues to drive innovation and excellence in the world of immunotherapy and regenerative medicine.

Antonio Sfiligoj

Director at VivaBioCell

Antonio Sfiligoj is a visionary leader in automated cell therapy products (ATMPs) manufacturing. He has been leading VivaBioCell with innovative research to scale production and lower ATMP costs, ultimately making new therapies more accessible to patients. His contributions have been transformative in advancing ATMP manufacturing, and his collaborations have been instrumental in driving progress within the industry.

Joseph P. Taormino, PhD

B.A. European Patent Attorney

Dr. Joseph P. Taormino, a European Patent Attorney since 1998, specializes in Biotechnology litigation at Hoffmann Eitle. As a co-leader of the Biotechnology practice group from 2002-2022, his practice centred on EPO opposition/appeal proceedings, due diligence in acquisitions and cross-border litigation strategy. With a wealth of experience, he continues to advise medium to large biotech and pharmaceutical firms, aligning legal strategies with their business needs. Notably, Joe has contributed to a number of significant EPO Board of Appeal decisions, published patent law and biotech articles and served as an advisor/rapporteur to the European Commission Expert Group in 2016.